Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients - Wikidata - awgldk - TriplyDB

Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients

Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients

http://www.wikidata.org/entity/Q34571746

about

Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin PharmGKB summary: very important pharmacogene information for CYP4F2 Warfarin pharmacogenetics.Warfarin dose requirement in Turkish patients: the influences of patient characteristics and polymorphisms in CYP2C9, VKORC1 and factor VII Copy number variation and warfarin dosing: evaluation of CYP2C9, VKORC1, CYP4F2, GGCX and CALU CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.Association between SIRT1 Gene Polymorphisms and Breast Cancer in Egyptians The Impact of Genetic and Non-Genetic Factors on Warfarin Dose Prediction in MENA Region: A Systematic Review.The future of warfarin pharmacogenetics in under-represented minority groups.Personalized medicine: is it a pharmacogenetic mirage?Factors influencing warfarin response in hospitalized patients.Personalized approach of medication by indirect anticoagulants tailored to the patient-Russian context: what are the prospects?Impact of GGCX, STX1B and FPGS Polymorphisms on Warfarin Dose Requirements in European-Americans and Egyptians.Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population.Association of apolipoprotein E (APOE) polymorphisms with warfarin maintenance dose in a northern Han Chinese population Pharmacogenomics of warfarin in populations of African descent.Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.Genetic variation and haplotype structure of the gene Vitamin K epoxide reductase complex, subunit 1 in the Tamilian population.Vitamin K nutrition, metabolism, and requirements: current concepts and future research.Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement Impact of Genetic Polymorphisms on Phenytoin Pharmacokinetics and Clinical Outcomes in the Middle East and North Africa Region.Influence of APOE Gene Polymorphism on Interindividual and Interethnic Warfarin Dosage Requirement: A Systematic Review and Meta-Analysis.Factors affecting warfarin dose requirements and quality of anticoagulation in adult Egyptian patients: role of gene polymorphism.Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.Is there a role for MDR1, EPHX1 and protein Z gene variants in modulation of warfarin dosage? a study on a cohort of the Egyptian population.Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets.Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.Frequency of Common CYP2C9 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis.Frequency of selected single nucleotide polymorphisms influencing the warfarin pharmacogenetics in Slovak population.Frequency of CYP2C9 and VKORC1 gene polymorphisms and their influence on warfarin dose in Egyptian pediatric patients.Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.Influence of VKORC1 and CYP2C9 Polymorphisms on Daily Acenocoumarol Dose Requirement in South Indian Patients With Mechanical Heart Valves.Effect of gene polymorphims on the warfarin treatment at initial stage.An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population.

P2860

Q26823542-64626CE4-683C-4668-BE28-EB350595BCEA Q28276514-53929B24-78B0-4DDE-8AC5-F04799A4E9BC Q34664072-7E279506-8C82-44FC-A7A0-79D0A9C00007 Q34785072-B73C7257-7AE8-4495-A3FB-C88D3052A056 Q35678294-42FC8A6E-65F0-461A-B447-390C92BDCD4A Q35795982-D634FFF1-3C72-4ED2-96DC-486014B75AD6 Q35913092-56B5E25D-191A-48A0-9B6F-E2673BFEFCAF Q35964875-B2A21BA1-1B2A-4D0D-9714-2E02C0F72A0D Q36228428-1699347F-86AF-40D7-96DA-4BD1B3294D95 Q36294461-2C10657E-583E-4642-8521-02C248BF0D4B Q36336007-CDC04169-64B6-4E63-A0FF-D1A2CE84C282 Q36346124-93A1D582-3C20-412D-9C58-E50294D418F6 Q36380430-91CC3DC9-9B32-4BD5-B53A-34C43EE881DC Q36599219-E26957B0-FD0C-4D05-91E0-86180060811C Q36599251-297AC098-2ABA-46D0-9A63-81797220D734 Q36611995-632A2C51-22D5-495F-8D82-29A96A7A0F93 Q36629209-11635EAD-14E6-4FDD-A9B9-4DE26D8E0317 Q36651620-88D63FB3-FBE5-4E9D-8C54-5B723DD165E9 Q36813817-3E66CA79-52AC-42E3-956B-2275B2869826 Q36828726-B0680F90-94EC-498B-AA91-D007E3BD596D Q37065161-62E34646-CDDD-40C6-B075-954C9F1DDB04 Q37138272-E4A433FA-7424-45E5-AC49-AEE8DB1A7AA9 Q37606335-76E68948-E17C-4C2D-9B5F-251330317752 Q38651234-E5CFB069-A76D-4967-A26A-0B4753C67E32 Q38803472-BF72E57B-4B0B-478A-B19D-28876A23E459 Q38897899-FFAEA080-C90E-4EA8-92B2-4FEE43C219A2 Q38897904-0DAB49E6-F93E-41E6-A3C4-FEBA7718D24F Q38983845-F8A53E55-039D-4F69-A3B1-CA6FCD7D328B Q39096673-37E342BE-F617-42D3-A3FB-D79EB569D39C Q39159490-58943101-438B-4387-9A1E-A60F2AF8BC68 Q39262868-65D0F40E-4825-4C71-9EAD-8B22021DE45E Q39537454-04185765-4033-45BA-B098-01B79C4FC579 Q39676335-CB082833-6962-46F7-AC88-22630D0A9B7B Q41356186-756E7A72-9477-4DD8-BCE3-8D50D2BD8EE4 Q42705932-ADAED31A-E1BE-4F80-AF86-E1B8F9B0E14D Q44367614-EA6BD6C6-3AE7-42A8-8EC0-56375D7C309E Q44495777-B45CC3BE-E3DD-4BDB-97E7-B56A47122EAF Q47996412-A38C337A-3DF0-415E-85C8-676EEA0EA0AC Q48905886-F3718E1D-A04F-4DF5-97AE-273969839C6E Q50993101-E6E0A7DE-5A93-416B-8E99-4434DCDC9C40

P2860

Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients

http://www.wikidata.org/entity/Q34571746

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Genetic and nongenetic factors ...... uirements in Egyptian patients

@ast

Genetic and nongenetic factors ...... uirements in Egyptian patients

@en

Genetic and nongenetic factors ...... uirements in Egyptian patients

@nl

type

label

Genetic and nongenetic factors ...... uirements in Egyptian patients

@ast

Genetic and nongenetic factors ...... uirements in Egyptian patients

@en

Genetic and nongenetic factors ...... uirements in Egyptian patients

@nl

prefLabel

Genetic and nongenetic factors ...... uirements in Egyptian patients

@ast

Genetic and nongenetic factors ...... uirements in Egyptian patients

@en

Genetic and nongenetic factors ...... uirements in Egyptian patients

@nl

P1433

Q34571746-906B7F0D-328D-4871-A37A-F35C9C4D4A51

P1476

Q34571746-1F1314A4-D891-4B63-99F2-F01509745DCF

P2093

Q34571746-02491158-578D-4606-BD38-69CB778A05B5

Q34571746-106565EF-3316-4581-9F59-B27EC1B80F96

Q34571746-19A3B105-BAA8-420C-8F34-FD63F1D39594

Q34571746-248C3890-9478-4D3D-B1A5-9F7571C29371

Q34571746-5069317D-4471-433E-AED5-A93CBA19C608

Q34571746-50D15021-C66C-4318-88E1-5AFAC2A6CFC8

Q34571746-54891438-0BBA-4E8F-8597-C7282ECFFD60

Q34571746-65E18950-C60D-42ED-85E5-898049E6557F

Q34571746-F3EA78BF-509D-42CD-B0B7-2B867DF9B9F8

P2860

Q34571746-14FF5E70-488F-41C1-8016-2B14F409DC28

Q34571746-2EE57E15-E7C5-439A-B55C-DB8134F49C3E

Q34571746-3D901A8A-76F5-482B-B257-4F7C132000CF

Q34571746-40C05130-949F-4270-A582-516488169438

Q34571746-49D3DCA1-D458-490C-BF7E-4E25571F55E1

Q34571746-5F1FABA6-638B-455A-9B73-411778C23B7F

Q34571746-6028AE49-234C-40D1-95B3-9519D97574A5

Q34571746-76872D51-9789-4852-88E3-0C10DD190C71

Q34571746-8ABFDA29-CD5C-44C6-A976-C2D8511FC88F

Q34571746-93C002E2-0242-4F3C-9000-AA8D7169DE0D

P304

Q34571746-3D5F1230-023D-4D67-901C-681163EC77DC

P31

Q34571746-CEB7BB14-89C6-45A5-B118-89079F4EF562

P356

Q34571746-B3F54BE4-DFC5-4DC7-9A06-6214080C1644

P433

Q34571746-FE36B037-E161-4890-8A9E-7FF28B225DDE

P478

Q34571746-1F93D365-76DF-429F-AF2C-59624DF1CA68

P50

Q34571746-5773BB5F-E234-492F-8241-0FD420C92BD8

P577

Q34571746-112164A5-46D9-48B4-8CA9-205E9B484E08

P698

Q34571746-F18D3C1C-9B3A-4F48-A069-9DAC0F76C069

P921

Q34571746-D6942D66-B847-4152-9940-4C2A5095D45A

P932

Q34571746-A9FB01A7-CD0C-428C-985B-1C2EEFC4449A

P356

FPC.0B013E3283436B86

P1433

Pharmacogenetics and Genomics

P1476

Genetic and nongenetic factors ...... uirements in Egyptian patients

@en

P2093

Julie A Johnson

http://www.w3.org/2001/XMLSchema#string

Lamiaa N Hammad

http://www.w3.org/2001/XMLSchema#string

Mohamed Hossam A Shahin

http://www.w3.org/2001/XMLSchema#string

Mohamed T H Sallam

http://www.w3.org/2001/XMLSchema#string

Mohamed-Eslam F Mohamed

http://www.w3.org/2001/XMLSchema#string

Mostafa El Shafey

http://www.w3.org/2001/XMLSchema#string

Shawky S Ali

http://www.w3.org/2001/XMLSchema#string

Taimour Langaee

http://www.w3.org/2001/XMLSchema#string

Yan Gong

http://www.w3.org/2001/XMLSchema#string

P2860

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose

A comparison of bayesian methods for haplotype reconstruction from population genotype data.

Estimation of the warfarin dose with clinical and pharmacogenetic data.

A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

CYP4F2 genetic variant alters required warfarin dose

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

Association of warfarin dose with genes involved in its action and metabolism.

Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.

Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients

Dosing algorithms to predict warfarin maintenance dose in Caucasians and African Americans

P304

130-135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/FPC.0B013E3283436B86

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Sherief I Khalifa

P577

2011-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21228733

http://www.w3.org/2001/XMLSchema#string

P921

P932

3038469

http://www.w3.org/2001/XMLSchema#string